Navigation Links
8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar

Positive Results in Patients With Follicular Lymphoma Reported Today at ASCO Annual Meeting

PHILADELPHIA, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline plc announced today long-term efficacy data from a Phase II trial of a single one-week course of frontline treatment with the BEXXAR(R) Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in 76 patients with newly diagnosed advanced follicular non-Hodgkin's lymphoma (NHL). This regimen was found to induce durable clinical and molecular remissions in patients with this disease. Specifically, researchers reported that patients who received a single one-week treatment of BEXXAR as monotherapy achieved estimated 8-year and 10-year overall survival (OS) rates of 86%. Additionally, 50% of patients survived without progression of disease at 8 years following therapy. For patients who achieved complete remission, the median time before their disease progressed was 9.2 years. An overall response rate and complete remission rate of 95% and 75%, respectively, were observed. These data were presented today at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois (Abstract #8033).(1)

"For years we have known that radioimmunotherapy, such as BEXXAR, is an effective treatment for patients with relapsed or refractory lymphoma. The data from this frontline study suggest that BEXXAR may also have activity when used as a frontline treatment and should be studied further in this setting. Of note, these results were achieved with BEXXAR given as a single treatment, completed within one week, which made it a convenient regimen for these patients," said Mark Kaminski, Professor of Internal Medicine and Director, Leukemia/Lymphoma Program at the University of Michigan and lead investigator of this study.

The five-year follow-up data from this study were originally reported in the New England Journal of Medicine (NEJM 352:441,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
2. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
3. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
4. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
5. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
6. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
7. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
8. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
9. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Post Your Comments:
(Date:9/16/2014)...  Denovo Biopharma, LLC, today announced that it ... Eli Lilly and Company (NYSE:  LLY). Denovo gains ... globally, including transfer of all intellectual property and ... Lilly developed enzastaurin in a variety of indications, ... trials for diffuse large B-cell lymphoma (DLBCL). In ...
(Date:9/16/2014)... -- EHE International, the recognized leader in preventive medicine and ... that David Abrams M.D . in Tarzana, ... center. Through David Abrams M.D ., EHE members in ... access to EHE,s preventive care programs to help proactively maintain ... Dr. Abrams M.D. to its growing private provider network. With ...
(Date:9/16/2014)... , Sept. 16, 2014  Advanced Medical ... stage development company engaged primarily in the ... for diagnostic and therapeutic applications, today announced ... related to its brachytherapy products.  AMIC,s rights ... its license from Battelle, under which AMIC ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2EHE International Certifies David Abrams M.D. as Its Newest Partner 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... guide low-income,and minority cancer patients through cancer treatment, ... major obstacles that prevent them,from receiving quality care ... October 28, 2007, at the American Society for ... Angeles. Minority and low-income cancer patients continue ...
... FLUSHING, N.Y., Oct. 30 The following is,being issued by New York Hospital Queens:, ... aureus(MRSA) is scheduled for ... James Rahal, M.D., and a team of infectious disease ... will address the ...
Cached Medicine Technology:Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments 2Hospital to Hold MRSA Briefing for Media and Community Leaders 2
(Date:9/16/2014)... CALIF. (PRWEB) September 16, 2014 ... and customer service solutions, announced today that the ... in Learning Award for the creation of a ... contractor agents. Brandon Hall Group honors companies that ... processes, systems and tools that have helped companies ...
(Date:9/16/2014)... 2014 As part of Child Passenger ... Saturday, Sept. 20, Amica Insurance is reminding ... and secure while in the car. , According to ... Safety Administration (NHTSA), 20 percent of drivers of ... manual when installing child restraints. However, 90 percent of ...
(Date:9/16/2014)... 2014 RxAnte, the leading platform ... targeted clinical programs, today announced key changes to ... Company’s drive to improve medication effectiveness through the ... On September 2, 2014, Brock Hardaway, chief executive ... that RxAnte founder and President Josh Benner has ...
(Date:9/16/2014)... Hudson County, NJ (PRWEB) September 16, 2014 ... that a leading Bariatric Surgeon, Leigh Montes, MD, ... of Bariatric Surgery at Christ Hospital. Our system ... Bariatric Center, a medical and surgical weight loss ... through the most advanced bariatric surgery procedures, including ...
(Date:9/16/2014)... 2014 Regulatory intelligence (RI), the ... has become a crucial skill for regulatory professionals ... sectors. Regulatory Intelligence 101 , new from ... serves as an essential guide to the basics ... examines available regulatory intelligence tools, both free and ...
Breaking Medicine News(10 mins):Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 2Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 3Health News:LiveOps Wins Silver At The 2014 Brandon Hall Group Excellence In Learning Awards For Best Use Of Social/Collaborative Learning 4Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Top Bariatric Surgeon Joins CarePoint Health 2Health News:Top Bariatric Surgeon Joins CarePoint Health 3Health News:RAPS Publishes Regulatory Intelligence 101 Book 2
... who showed that a single prostate specific antigen (PSA) test ... prostate cancer up to 25 years later, (regardless of clinical ... used to predict advanced prostate cancer. , The findings, ... help physicians identify which men would benefit from intensive screening. ...
... for,International Development (USAID) announced a $70 million, five-year,program ... countries.,Fistula Care aims to increase access to emergency ... their capacity to provide surgical,fistula repair. The program ... increase understanding about obstetric fistula and steps to,prevent ...
... His Royal Highness, The Duke of York,was the ... to mark the United States,launch of UK-based specialty ... US product, Sancuso, is currently under,consideration for licensing ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080214/NYTH111 ), Prince Andrew ...
... the human cell, certain proteins are the production managers, ... the National Institute of General Medical Sciences (NIGMS), part ... clearer understanding of how a key protein controls gene ... disease. The work could provide new avenues to design ...
... MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the first quarter, ended,December 31, ... Highlights: - EP Revenue for Q1 2008 ... over Q1 2007. All regions around ...
... SANTA MONICA, Calif., Feb. 14 /PRNewswire-USNewswire/ - The ... letter to the state,s HMO,regulator calling for swift ... as "double agents," combing medical records for any,excuse ... Governor Arnold Schwarzenegger told the Los Angeles Times ...
Cached Medicine News:Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:USAID Awards $70 Million for the Prevention and Treatment of Obstetric Fistula 2Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 2Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 3Health News:Enzyme structure reveals new drug targets for cancer and other diseases 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 3Health News:CryoCath Announces Fiscal 2008 First Quarter Results 4Health News:CryoCath Announces Fiscal 2008 First Quarter Results 5Health News:CryoCath Announces Fiscal 2008 First Quarter Results 6Health News:CryoCath Announces Fiscal 2008 First Quarter Results 7Health News:CryoCath Announces Fiscal 2008 First Quarter Results 8Health News:CryoCath Announces Fiscal 2008 First Quarter Results 9Health News:CryoCath Announces Fiscal 2008 First Quarter Results 10Health News:CryoCath Announces Fiscal 2008 First Quarter Results 11Health News:FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: